What is KZR's current stock price?

KZR (Kezar Life Sciences, Inc.) is currently trading at $7.29 with a market cap of $53.9M.

What sector is Kezar Life Sciences, Inc. in?

Kezar Life Sciences, Inc. (KZR) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is KZR a good stock to buy?

Analysts have a Hold consensus on KZR with a price target of $11.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

KZR Kezar Life Sciences, Inc.

Healthcare

$7.29+0.00%ClosedMarket Cap: $53.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.82

P/S

0.00

EV/EBITDA

0.28

DCF Value

$9.69

FCF Yield

-78.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-58.4%

ROA

-66.5%

ROIC

-63.1%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-5.8M	$—
Q4 null	$0.00	$-14.5M	$—
FY null	$0.00	$-56.0M	$—
Q3 null	$0.00	$-11.2M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$11.00

Target (Median)

$7.00

Target Range

$5.00 - $21.00

0 Strong Buy0 Buy3 Hold0 Sell0 Strong Sell

Wells FargoEqual Weight

2025-10-17

JefferiesHold

2025-10-17

William BlairMarket Perform

2025-10-17

HC Wainwright & Co.Neutral

2025-07-16

Trading Activity

Insider Trades

View All

Wallace Courtneydirector

SellMon May 11

Wallace Courtneydirector

SellMon May 11

Wallace Courtneydirector

SellMon May 11

Schiller Mark C.officer: Chief Operating Officer

SellMon May 11

Schiller Mark C.officer: Chief Operating Officer

SellMon May 11

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.41

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.

Peers